BIOATLA, INC. Accounts Receivable
BIOATLA, INC. (BCAB) had Accounts Receivable of $2.00 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-08-13
- 2026-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $2.00M.
- 2025-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $0.00.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2026-06-30 | $2.00M 10-Q · filed 2026-08-13 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |